STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR’s Executive Committee and report to Warren Foust, President and Chief Executive Officer.

“Evolving STAAR from a single-product focus into a multi-product platform is central to our strategy — and requires the right leader,” said Mr. Foust. “Ben Park is that leader. We have been delivering on revenue growth and profitability, and now it’s time to match that momentum with equal urgency on innovation. With our R&D and Advanced Research teams preparing for first-in-human studies of our next-generation products, the moment to accelerate is now. Ben’s track record of success in building and commercializing breakthrough medical device platforms makes him the ideal person to advance our innovation roadmap and unlock the full potential of our proprietary Collamer® technology.”

Dr. Park joins STAAR from Align Technology, Inc., where he served as Head of Emerging Technology since 2018. In that role, Dr. Park built and led a global multidisciplinary team — spanning biomedical engineering, hardware, embedded systems, and software across the U.S. and APAC — to define next generation product platforms and address unmet clinical needs, from concept through to market launch.

“STAAR has built something genuinely rare — a clinically proven product portfolio with over 30 years of real-world results, a proprietary material that no one else has, and a market opportunity that is only growing as myopia becomes one of the defining health challenges of our time,” said Dr. Park. “What drew me here is the ambition to go further: to take everything STAAR has learned and apply it across myopia and beyond. I see a real opportunity to build a multi-product platform by bringing a fresh perspective to how we identify and solve unmet clinical needs. This team is ready to execute, and I’m energized to help accelerate what we can deliver together — for surgeons, for patients, and for the future of refractive surgery.”

Prior to Align, Dr. Park served as Chief Technology Officer of Fingertips Lab, Inc., where he led the development and commercial launch of a health technology product designed for the visually impaired in markets across more than 10 countries. Prior to Fingertips Lab, he served as Chief Technologist at Volcano Corporation, where he led the development of a novel intracardiac imaging platform. He also co-founded Fluid Medical, Inc., where he invented a new intravascular ultrasound imaging platform utilizing shape memory alloy materials and forged strategic development partnerships with Boston Scientific and Olympus Corporation. Dr. Park was awarded the Dean’s Postdoctoral Fellowship at the Stanford University School of Medicine, and holds a Ph.D. in Mechanical Engineering from Stanford University. Dr. Park has authored more than 40 patents and peer-reviewed research publications.

Dr. Park will join other STAAR executives and leaders at the upcoming 44th Congress of the ESCRS in London from September 11–15, 2026, where the Company will engage with ophthalmic surgeons and industry leaders from around the world.

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the Company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.discoverICL.com. To learn more about STAAR, visit www.staar.com.

We intend to use our website as a means of disclosing material non-public information about the Company and for complying with Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at investors.staar.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as “anticipate,” “believe,” “expect,” “plan,” “estimate,” “project,” “continue,” “will,” “should,” “may,” and similar terms. All statements in this press release that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: our ability to grow and generate profit; our reliance on independent distributors in international markets; a slowdown or disruption to the Chinese economy; global economic and geopolitical conditions; disruptions in our supply chain; fluctuations in foreign currency exchange rates; international trade disputes (including involving tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal manufacturing facility; competition; potential losses due to product liability claims; our exposure to environmental liability; data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations; acquisitions of new technologies; climate changes; the willingness of surgeons and patients to adopt a new or improved product and procedure; extensive clinical trials and resources devoted to research and development; compliance with government regulations; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; laws pertaining to healthcare fraud and abuse; changes in FDA or international regulations related to product approval; product recalls or failures; and other important factors set forth in the Company’s Annual Report on Form 10-K for the year ended January 2, 2026 under the caption “Risk Factors,” which is filed with the Securities and Exchange Commission (the “SEC”) and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings,” as any such factors may be updated from time to time in the Company’s other filings with the SEC.

Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media gallery

About The Author
Business Wire